WS Amati Global Innovation Fund on Repligen Corporation
Thesis
Repligen supplies equipment used in biomanufacturing and reported strong results during the period. Re-shoring of drug manufacturing to the US is contributing to demand for its products. The fund also expects long-term demand growth from biologic drugs and other novel therapy categories. It continues to hold a substantial position.
“This adds to the long-term demand growth from biologic drugs and other novel therapy categories”
Key risks
- Higher interest rates can pressure growth-company valuations and delay investment projects